Physician profile
Philip W Poor
NPI 1013022433
$14,727.00
in general payments reported to CMS, 2019-2025
39 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,394 · 2020: $2,287 · 2021: $2,292 · 2022: $2,158 · 2023: $2,082 · 2024: $2,515.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,547 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,546.73 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,849.56 | 2019-2024 | Enbrel, Otezla, Tavneos |
| Abbvie INC. | $1,906.79 | 2019-2024 | |
| Janssen Biotech, INC. | $1,751.12 | 2019-2024 | Tremfya, Remicade, Simponi |
| Novartis Pharmaceuticals Corporation | $1,443.73 | 2019-2024 | |
| Glaxosmithkline, LLC. | $901.92 | 2019-2024 | Benlysta |
| Pfizer INC. | $642.05 | 2019-2024 | |
| Mallinckrodt Hospital Products INC. | $625.41 | 2020-2024 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $479.05 | 2020-2024 | Ofev, Cyltezo |
| Genentech USA, INC. | $451.40 | 2019-2024 | Actemra |
| Fresenius Kabi USA, LLC | $387.05 | 2023-2024 | Idacio |
| Radius Health, INC. | $365.04 | 2019-2024 | Tymlos |
| Horizon Therapeutics Plc | $342.45 | 2019-2020 | |
| Ucb, INC. | $315.97 | 2019-2024 | Cimzia, Bimzelx |
| Aurinia Pharma U.S., INC. | $246.72 | 2021-2024 | Lupkynis |
| Ani Pharmaceuticals, INC. | $209.32 | 2022-2024 | Purified Cortrophin Gel |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Poor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.